The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Methodological assessment of HCC literature
Daniele G, Costa N, Lorusso V, Costa-Maia J, Pache I, Pirisi M. Ann Oncol. 2013 Apr;24 Suppl 2:ii6-14. doi: 10.1093/annonc/mdt052.
Source
Clinical Trials Unit, National Cancer Institute of Naples, Naples, Italy. gennaro.daniele@usc-intnapoli.net
Abstract
Despite the fact that the hepatocellular carcinoma (HCC) represents a major health problem, very few interventions are available for this disease, and only sorafenib is approved for the treatment of advanced disease. Of note, only very few interventions have been thoroughly evaluated over time for HCC patients compared with several hundreds in other, equally highly lethal, tumours. Additionally, clinical trials in HCC have often been questioned for poor design and methodological issues. As a consequence, a gap between what is measured in clinical trials and what clinicians have to face in daily practice often occurs. As a result of this scenario, even the most recent guidelines for treatment of HCC patients use low strength evidence to make recommendations. In this review, we will discuss some of the potential methodological issues hindering a rational development of new treatments for HCC patients.